Smart Insulin Pen Market, By Indication (Type 1 Diabetes, Type 2 Diabetes), By Connectivity (Bluetooth, USB), By Distribution Channel (Clinics and Ambulatory Surgical Centers, e-Commerce, Retail Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Jul 2023

Code : CMI3436

Pages :105

Formats :

Excel and PDF

Industry : Medical Devices

Market News

Global Smart Insulin Pen Market: Key Developments

In June 2021, Novo Nordisk Pharma, a U.S. based healthcare company, announced that it had obtained Japanese regulatory approval from Pharmaceuticals and Medical Devices Agency for NovoPen 6 and NovoPen Echo Plus as medical devices, the first smart insulin pens to be approved in the country.

In May 2021, Eli Lilly and Company, a U.S. based pharmaceutical company, announced that it had signed strategic international agreements with four companies – DexCom, Inc., U.S. based manufacturer of glucose monitoring system, Glooko Inc.,U.S. based software company for diabetes mobile applications, myDiabby Healthcare, France based medical software company and Roche, a Switzerland-based pharmaceutical company – to advance connected solutions and streamline care for people living with diabetes in markets outside of the U.S.

In November 2022, Novo Nordisk, a Denmark based pharmaceutical company, announced that its smart insulin pens can now be connected to the Abbott FreeStyle LibreLink app.

In March 2022, Glooko Inc., a U.S. based provider of remote patient monitoring and data management solutions for diabetes and other chronic diseases, announced the acquisition of DIABNEXT. DIABNEXT is a France-based company offers a telemedicine platform that helps diabetic patients better manage their disease and stay in touch remotely with the health professionals who follow them to improve the balance of their diabetes. The DIABNEXT mobile application completes Glooko's product portfolio.